129770761449218750_131Analysts believe that, while access to health care directory can promote company products volume, but with the deepening of reform of medical, "Sue peptide" and "Shu Taiqing" Government may face downward price risk, and that may have some effect on the operating results of the company show weakness in the market this week, but seems to have no Shu Taishen (300,204) (300,204. SZ) gained strong momentum.
As of March 23, Shu Taishen per cent to $ 78, full week trend rose 7.64%.
Behind this, Shu Taishen apart from a pretty good annual performance, has released a high take transfer programme. Although the performance indicators are doing well, but market participants believe that, after aAfter rising, the company shares have been "sitting", which contains many risks, "room in the later estimates will not be too great."
So the view that pharmaceutical stocks investment value? Increase in performance in 2011 80% access to information displayed, weichang shutai God is mainly engaged in biological products and part of research and development, production and sales of chemicals, Main export products mouse nerve growth factor for injection "Su peptide" and polyethylene glycol-electrolyte powder "Shu Taiqing", where "Su peptide" is State class new medicine, mainly for neuroprotection and repair nerve damage "Shu Taiqing" are four State class new medicine, mainly for clearing intestinal and treatment of constipation. In 2011, the company achieved revenues of $ 206 million, over theYear over year growth 60.53%, belong to shareholders of listed company's net profit of $ 104 million, up 81.32% over the previous year, and basically achieve earnings per share of $ 156 million.
Where "Su peptide" revenues of 180 million Yuan, an increase of 65%, total revenue ratio of 88.06%, is the company's main sources of performance. "Su peptides"In 2009 National Healthcare directory b class variety, the company increased marketing efforts and develop new channels, making Su peptide sales last year hospitals increased to 1600.
The second half of last year, health effects begin to emerge, four quarters "Su peptide" 40% per cent increase in income, net profit increased 79%
tera gold, observed apparent. "Shu Tai God nerve drugsDoes have a larger development prospects. Current nerve repair in China market at around 10 billion a year, company product market space larger.
"Investment consultants said Liu Wei, a researcher at the pharmaceutical industry. Currently, there were three other companies in China rat nerve growth factor for injection respectively as North Road "nobex", Wuhan Hite "road home", as well as LiPearl Group (000513) "Li leisure".
From Soochow securities (601,555) according to research data, "Sue peptide" in market share in the third quarter of last year to 48.17%, in a leading position. Main products of the company of another Shu Taiqing complete income of more than 22 million Yuan last year, an increase of 62%. As of last year, "SuePeptide "and" Shu Taiqing "has maintained a very high gross margins, and 91.86%, respectively. Main products keep prices expected note was, in 2009, Sue peptide was included in the catalogue for the health insurance of health (2009 Edition) and retail prices will be limited by the Government, and "Shu Taiqing" has been included in the catalogue for the health insurance (2004 edition), the law on health care directory (2009 Edition), by the national development and Reform Commission has been priced, limit the maximum retail price. Analysts believe that, while access to health care directory can promote company products volume, but with the deepening of reform of medical, "Sue peptide" and "Shu Taiqing" Government may face downward price risk, and that may be the companyHave some impact business performance. "Due to Shu Taishen two leading products Sue peptides and Shu Taiqing is listed in the healthcare directories, its retail price will be Government qualifies drugs of the future price trend is likely to is getting cheaper, future companies that are expected two products price will likely declined.
"Liu Wei said. Before the securities released reportsSaid the company's main products there is a price reduction is expected, once the cut is too large, ex-factory price of the affected companies, may cause a sharp drop in the company's sales revenue and gross margin. Enter healthcare catalog product prices may decline in expected did not affect the company's performance in the near future, in addition to the high growth of the annual report, the company's first-quarter performance is quite good。
Shu Taishen notice recently published its results for the first quarter of 2012, expected in 2012 a quarter the net profit attributable to the shareholders of listed companies for the 30 million ~4000 million, an increase of 185%~215%, corresponding to earnings per share of $ 0.45~0.60, continued its high growth. Analysts from the companyIncrease the performance of the first quarter
tera power leveling, 2011 yahuo a quarter of agent is not obvious.
Superior sales performance reflects the marketing effectiveness of reforms.
Valuations higher up limited space? Since the market rebound in January, Shu Taishen share price buoyant, from more than 50 Yuan rose to more than 80 historical high of more than $ go to PakShare camp March weather. "The smooth performance of the company, now still in a bull market, but the market itself is a lot of risk.
"A brokerage analyst said. First capital published study reported that companies in a period of rapid growth, growing more determined, but valuations are not low, giving the "prudence recommended" rating.Dynamic price-earnings ratio, for example, according to the March 23, Shu Taishen 49.9 times times, comparable companies on the gem Watson bio (300142) (300142.SZ), Anke biotechnology (300,009) (300,009. SZ), intellectual flying organism (300,122) (300,122. SZ)-29.42 times times, 35.75 times times, three times.
This shows that Shu Taishen index after the wisdom of flying creatures, and significantly higher than the other two companies. As of now, there were 90 institutions on Shu Taishen 2012 annual forecast, forecast an average net income of $ 134 million, up 28.94% over the previous year
tera gold, the average forecast per share chargeBenefits for $ 1.89. Risk tips products price risk, and Medicare payment reform will have a greater impact on product sales; a single risk, once the core product "Su peptide" facing intensified competition in the market or other issues, will greatly affect the normal operations of the company as a whole.
Others:
No comments:
Post a Comment